Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease

Ae Ryoung Park, Hyen Oh La, Byung Sik Cho, Soon Joo Kim, Byung Koo Lee, Jeong Yeon Rhie, Hye Sun Gwak

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Purpose. The results of a prospective study of topical budesonide versus topical dexamethasone therapy for oral manifestations of chronic graft-versus-host disease (cGVHD) are presented. Copyright

Methods. In a prospective single-center investigation, a cohort of patients who developed oral symptoms of cGVHD after allogeneic stem cell transplantation were assigned to topical treatment with 0.03% budesonide rinse (group A, n = 26) or 0.01% dexamethasone rinse (group B, n = 24). Diagnosis of oral cGVHD symptoms, clinical staging, and treatment response scoring were performed at baseline and one month later according to current National Institutes of Health consensus criteria.

Results. At one-month follow-up, there was a significant decrease in the median oral cGVHD examination score in both groups (p < 0.001); the decrease in the median examination score was greater with budesonide versus dexamethasone therapy (2.5 points versus 1.0 point, p = 0.045). The rates of overall treatment response, including complete and partial responses, were 53.8% and 29.2% in groups A and B, respectively (p = 0.093). In addition, there was a significant decrease from baseline in the median self-rated oral pain severity score in group A (p < 0.001).

Conclusion. Patients who received topical budesonide or dexamethasone rinse to treat oral manifestations of cGVHD had decreased cGVHD severity and pain scores after 30 days compared with baseline scores, though no statistical differences were seen between groups.

Original languageEnglish
Pages (from-to)1383-1391
Number of pages9
JournalAmerican Journal of Health-System Pharmacy
Volume70
Issue number16
DOIs
StatePublished - 15 Aug 2013

Fingerprint

Dive into the research topics of 'Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this